Predictive Oncology Announces $7.2 Million Registered Direct Offerings
In the first offering, the Company has entered into definitive agreements with several institutional investors for the issuance and sale of 3,837,280 shares of its common stock, at a purchase price of
In the second offering, the Company has entered into definitive agreements with several institutional investors for the issuance and sale of 8,162,720 shares of its common stock, at a purchase price of
The closings of the offerings are expected to occur on or about
The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) are being offered by the Company in the registered direct offerings pursuant to an effective “shelf” registration statement on Form S-3 (Registration No. 333-255582), including an accompanying base prospectus previously filed with the
The warrants being sold in the first offering described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
TumorGenesis is the company’s arm for research and development for zPREDICTA, Soluble Biotech and
This press release comprises of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "expects," "plans," "intends," "anticipates," "believes," "estimates," "seeks," variations of such words and similar expressions are intended to identify such forward-looking statements. Such risks and uncertainties include: market and other conditions, the completion of the registered direct offerings, the satisfaction of customary closing conditions related to the registered direct offerings and the intended use of net proceeds from the registered direct offerings. The forward looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the
Investor Relations Contact:
Source: Predictive Oncology Inc.